Ep.6 – Real-world experience with SGLT-2 inhibitor use – Prof Michael Böhm
26 Dec 2022
Episode 6 – Real-world experience with SGLT-2 inhibitor use – Prof Michael Böhm We are joined by Professor Michael Böhm. He is the director of the Clinic...
Topics
Latest Videos
Ep.5 – The use of SGLT2 inhibitors in patients hospitalised for acute heart failure – Prof. Christiane Angermann
16 Dec 2022
Episode 5 – The use of SGLT2 inhibitors in patients hospitalised for acute heart failure – Prof. Christiane Angermann We are joined by Professor Christiane...
Ep.4 – Treatment options in patients with heart failure across the spectrum of left ventricular ejection fraction with a particular interest in the pooling of previous results to gain greater insight – Dr. Milton Packer
02 Dec 2022
Episode 4 – Treatment options in patients with heart failure across the spectrum of left ventricular ejection fraction with a particular interest in the pooling...
Ep.3 – Potential Treatment Options: A Focus on Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction – Prof. Javed Butler
07 Nov 2022
Episode 3 – Potential Treatment Options: A Focus on Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Patients with Heart Failure with Reduced Ejection...
EP.2 – Potential Treatment Options with a Focus on Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Patients with Heart Failure with Preserved Ejection Fraction – Prof. Michael Böhm
14 Oct 2022
Episode 2 – Potential Treatment Options with a Focus on Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Patients with Heart Failure with Preserved Ejection...
EP.1 – Overview of Heart Failure with Preserved/Reduced Ejection Fraction with Prof. Stefan Anker
19 Aug 2022
Episode 1: Overview of Heart Failure with Preserved/Reduced Ejection Fraction In this episode, we are joined by Professor Stefan Anker. Professor Anker is based at the...
What are you doing in terms of continuation of oral anticoagulation during the procedure? – Professor Jan Steffel
15 Dec 2021
Dr Jan Steffel MD FESC FEHRA FHRS: Professor and Vice Chairman of the Department of Cardiology, Senior Consultant, Division of Electrophysiology & Cardiac Devices,...
Advancing cardiac diagnostics during COVID-19: Improving Hospital Efficiency & Safety with ICMs
11 Oct 2021
Chairperson: Prof. Thorsten Lewalter – Professor of Internal Medicine – Cardiology, University of Bonn; Head. Dept. of Cardiology and Intensive Care, Peter...
What role does the procedural or clinical complexity have in the decision of antithrombotic therapy? – Professor Jan Steffel
01 Sep 2021
Dr Jan Steffel MD FESC FEHRA FHRS: Professor and Vice Chairman of the Department of Cardiology, Senior Consultant, Division of Electrophysiology & Cardiac Devices,...
What do guidelines say for the post PCI antithrombotic therapy and are there differences between the US and EU? – Professor Jan Steffel
01 Sep 2021
Dr Jan Steffel MD FESC FEHRA FHRS: Professor and Vice Chairman of the Department of Cardiology, Senior Consultant, Division of Electrophysiology & Cardiac Devices,...
Shall the OAC be continued or stopped during PCI – What do the clinical trials say? – Professor Jan Steffel
01 Sep 2021
Dr Jan Steffel MD FESC FEHRA FHRS: Professor and Vice Chairman of the Department of Cardiology, Senior Consultant, Division of Electrophysiology & Cardiac...
NOACs in patients with atrial fibrillation: Insights from the cardiac cath lab – ESC Congress 2020: The Digital Experience
29 Nov 2020
Chairpersons John William Eikelboom (Hamilton, Canada) Dominick Joseph Angiolillo (Jacksonville, United States of America) Subtitle Sponsored by Boehringer Ingelheim...
Atrial fibrillation patients in focus: clinical cases and guidelines – ESC Congress 2020: The Digital Experience
29 Oct 2020
Chairpersons Gregory Yh Lip (Liverpool, United Kingdom of Great Britain & Northern Ireland) Elaine Hylek (Boston, United States of America) Subtitle Sponsored by...
What do we know about the 4 available post PCI studies and how could the guidelines take them into account? – Professor Jan Steffel
19 Oct 2020
Dr Jan Steffel MD FESC FEHRA FHRS: Professor and Vice Chairman of the Department of Cardiology, Senior Consultant, Division of Electrophysiology & Cardiac Devices,...
Dual versus triple antithrombotic therapy post PCI – what do the guidelines say, are there any similarities & differences between North America and EU? – Professor Jan Steffel
12 Oct 2020
Dr Jan Steffel MD FESC FEHRA FHRS: Professor and Vice Chairman of the Department of Cardiology, Senior Consultant, Division of Electrophysiology & Cardiac Devices,...
Dual versus triple antithrombotic therapy post PCI – What does the data with NOACs say? – Professor Jan Steffel
01 Jun 2020
Dr Jan Steffel MD FESC FEHRA FHRS: Professor and Vice Chairman of the Department of Cardiology, Senior Consultant, Division of Electrophysiology & Cardiac Devices,...
10 years since RE-LY: comprehensive experience for atrial fibrillation patients – ESC 2019
16 Mar 2020
Chairpersons: John William Eikelboom (Hamilton, Canada), Gregory Yh Lip Liverpool, United Kingdom) Subtitle: Sponsored by Boehringer Ingelheim Learning Objectives: To...
NOACs in patients undergoing cardiac procedures – ESC 2019
16 Mar 2020
Chairpersons: Christopher Paul Cannon (Boston, United States of America), Dominick Joseph Angiolillo (Jacksonville, United States of America) Subtitle: Sponsored by...
What do we know about dabigatran in elderly patients?
01 Oct 2019
Based on the patient characteristics of an elderly AF patient with renal impairment Dr. John W. Eikelboom will review existing data from multiple sources including...
What do we know about dabigatran in patients with cardiovascular disease?
01 Oct 2019
Based on the patient characteristics of an AF patient with cardiovascular comorbidities Dr. John W. Eikelboom will review existing data from multiple sources including...
Dabigatran, a direct thrombin inhibitor, reduces the risk of an intracerebral haemorrhage: Protection of the blood brain barrier
01 Oct 2019
This is a video showing the MOA of thrombin inhibition on intracranial haemorrhage. It shows how dabigatran, a thrombin inhibitor minimises thrombin mediated damage...
RE-DUAL PCI Congress Presentation and Q&A
01 Oct 2019
Congress Presentation presented at AHA 2017 given by Dr. Chris Cannon with slides on a neutral background ( only Study branding) Including Q&A with Dr. Cannon and...
Reversibility of NOAC therapies: the neurologist’s perspective – Prof. Dr. Martin Grond
01 Oct 2019
Neurologist’s Perspective of Reversal for Thrombolysis or ICH with Prof. Dr. Martin GrondThis adaptable 6 min video presents neurology cases from real clinical...
The RE-LY Trial – A landmark study in cardiology
01 Oct 2019
Communicate RE-LY data including subgroups data and leverage expert opinion from Dr. John W. Eikelboom to cover: Overview of safety/efficacy profile established in...
Interview with Oscar Oseroff, Secretary General: World Society of Arrhythmias
19 Sep 2019
Interview with Oscar Oseroff, Secretary General: World Society of Arrhythmias. In this interview he invites fellow friends and colleagues to join him at the World...
Dual antithrombotic therapy with Dabigatran in AF patients post PCI – Expert interview with Dr. Jur ten Berg
10 May 2019
Expert interview with Dr. Jur ten Berg about dual antithrombotic therapy with Dabigatran in AF patients post PCI. In the interview he focuses mainly on new subanalyses,...
Dual antithrombotic therapy with Dabigatran in AF patients post PCI – Professor Stefan Hohnloser
09 May 2019
Interview series with Professor Stefan Hohnloser about dual antithrombotic therapy with Dabigatran in AF patients post PCI Should dabigatran dual therapy be the default...
New Insights Into Post-PCI Care: The Re-Dual PCI Study
09 May 2019
Dr. Dominick Angiolillo summarizes the results of the RE-DUAL PCI study showing the safety of dabigatran dual therapy post-PCI with doses approved for stroke prevention...
Changing Clinical Practice The Re-Circuit Study
08 May 2019
In the video Dr. Gupta summarized the results of the RE-CIRCUIT study confirming the safety profile of dabigatran also in the setting of catheter ablation in AF...
RE-CIRCUIT Study of Peri-Procedural Anticoagulation in AF Ablation
08 May 2019
An infographic publication video summarizing the results of the RE-CIRCUIT study recently published in NEJM comprehensively in less than 2...
GLORIA-AF Final Phase II Two-year safety and effectiveness of dabigatran in AF patients (GYH Lip)
08 May 2019
Summary of GLORIA-AF Final Phase II: Two-year safety and effectiveness of dabigatran in patients with atrial fibrillation (summarized by Prof Gregory Lip). An...
From Clinical trials to RWE infographic animation (version with RE-LY EU label analysis)
03 May 2019
The series of infographic animations communicate the consistency of results, how RWE supports the favorable safety profile and the importance of RWE evidence. From...
Latest Posts
What do we know about the performance of the 150mg dose, in particular the REDUAL study for thromboembolic & major bleeding events? – Professor Steffel
26 Oct 2020
Dr Jan Steffel MD FESC FEHRA FHRS: Professor and Vice Chairman of the Department of Cardiology, Senior Consultant, Division of...